Lorazepam-Induced Toxicity in the Aged

NCT00044642 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2013-12-06

No results posted yet for this study

Summary

This study will compare the effects of an acute dose of lorazepam to a placebo in elderly patients with generalized anxiety disorder (GAD).

Conditions

  • Anxiety Disorders
  • Generalized Anxiety Disorder

Interventions

DRUG

Lorazepam

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH
  • Nathan Kline Institute for Psychiatric Research

    lead OTHER

Principal Investigators

  • Nunzio Pomara, MD · Nathan S. Kline Institute and New York University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-12-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044642 on ClinicalTrials.gov